- Home
- LPCN vs INTS Comparison
LPCN vs INTS Comparison
Compare LPCN & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- INTS
- Stock Information
- Founded
- LPCN 1997
- INTS 2012
- Country
- LPCN United States
- INTS United States
- Employees
- LPCN N/A
- INTS N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- INTS Health Care
- Exchange
- LPCN Nasdaq
- INTS Nasdaq
- Market Cap
- LPCN 16.1M
- INTS 8.0M
- IPO Year
- LPCN N/A
- INTS 2023
- Fundamental
- Price
- LPCN $3.27
- INTS $0.33
- Analyst Decision
- LPCN Strong Buy
- INTS Strong Buy
- Analyst Count
- LPCN 2
- INTS 3
- Target Price
- LPCN $9.00
- INTS $8.50
- AVG Volume (30 Days)
- LPCN 32.4K
- INTS 3.7M
- Earning Date
- LPCN 08-07-2025
- INTS 08-07-2025
- Dividend Yield
- LPCN N/A
- INTS N/A
- EPS Growth
- LPCN N/A
- INTS N/A
- EPS
- LPCN N/A
- INTS N/A
- Revenue
- LPCN $3,674,834.00
- INTS N/A
- Revenue This Year
- LPCN N/A
- INTS N/A
- Revenue Next Year
- LPCN N/A
- INTS N/A
- P/E Ratio
- LPCN N/A
- INTS N/A
- Revenue Growth
- LPCN N/A
- INTS N/A
- 52 Week Low
- LPCN $2.68
- INTS $0.26
- 52 Week High
- LPCN $7.90
- INTS $5.10
- Technical
- Relative Strength Index (RSI)
- LPCN 52.27
- INTS 41.29
- Support Level
- LPCN $3.10
- INTS $0.26
- Resistance Level
- LPCN $3.39
- INTS $0.32
- Average True Range (ATR)
- LPCN 0.18
- INTS 0.03
- MACD
- LPCN 0.02
- INTS 0.02
- Stochastic Oscillator
- LPCN 39.77
- INTS 62.56
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.